No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
COO240719C90000
- 0.75
- -1.43-65.60%
15min DelayClose Jul 19 16:00 ET
0.75High0.75Low
0.75Open2.18Pre Close1 Volume311 Open Interest90.00Strike Price75.00Turnover0.00%IV0.00%PremiumJul 19, 2024Expiry Date0.75Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma121.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Cooper Companies Raised to Buy at Jefferies on Valuation Disconnect
Cooper Cos Price Target Raised to $115.00/Share From $107.00 by Jefferies
Cooper Cos Price Target Raised to $115.00/Share From $107.00 by
Express News | Jefferies Upgrades Cooper Companies to Buy, Raises Price Target to $115
Is It Time To Consider Buying The Cooper Companies, Inc. (NASDAQ:COO)?
Let's talk about the popular The Cooper Companies, Inc. (NASDAQ:COO). The company's shares saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$98.92
Express News | Cooper Companies Inc : Jefferies Raises Target Price to $115 From $107
Cooper Cos Is Maintained at Overweight by Piper Sandler
Cooper Cos Is Maintained at Overweight by Piper Sandler
Comments
Investors maintain a high P/E ratio for Cooper Companies despite earnings decline, buoyed by strong forecasted growth. This is expected to continue supporting the share price.
Why Investors Shouldn't Be Surprised By The Cooper Companies, Inc.'s (NASDAQ:COO) P/E 1
Jonathan Banas, executive vice president and chief financial officer, expressed delight at the appointment of Nudd, praising her as an invaluable and energetic leader within the finance function at Cooper Standard.
Cooper Companies' decreasing ROCE and stagnant sales despite reinvestment don't suggest a potential multi-bagger. The past five-year return indicates awareness of these trends. Consider other options for a multi-bagger.
Baird advocates medtech companies such as Alcon, Stryker, and Cooper due to product and pricing strengths. Belief is strong in Alcon's 2024 margin possibilities, Stryker's premium pricing and predicted robust orthopedic demand, and projected revenue growth for Boston Scientific and Axonics.
Cooper Companies' high P/E ratio is backed by robust earnings growth outlook. Shareholders are holding onto their stocks due to the expected superior future earnings growth.
Read more